Navigation Links
Lexicon to Present at Stifel Nicolaus Healthcare Conference
Date:9/9/2010

THE WOODLANDS, Texas, Sept. 9 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Dr. Arthur T. Sands, president and chief executive officer, will present at the Stifel Nicolaus Healthcare Conference in Boston on Thursday, September 16, 2010 at 9:10 a.m. Eastern Time.

A live webcast of the presentation will be accessible through Lexicon's corporate website at www.lexpharma.com. An archived edition of the presentation will also be available for 30 days after the event.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Lexicon to Present at Morgan Stanley Global Healthcare Conference
2. Lexicon to Present at Two Major Healthcare Investor Conferences
3. Lexicon Announces Pricing of Common Stock in Public Offering
4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
5. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
6. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
8. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
9. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
10. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
11. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... Noblis, Inc., a leading ... a paper published this week in the scientific journal Viruses ( http://www.mdpi.com/1999-4915/7/6/2763 ), ... currently used to detect the Ebola virus. Noblis worked with the Department of ...
(Date:6/30/2015)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... on the development of autologous cell therapies, announced today ... clinical trial of RCT-01, being tested for the ... enrolled and their tissue biopsy sent for processing ... of non-bulbar dermal sheath (NBDS) cells isolated from ...
(Date:6/29/2015)... ... June 30, 2015 , ... This cutting edge standard making is a ... 12 distinct peaks, the WAV-8 is the world’s first cuvette-shaped, solid-state filter that lets ... the NIR range. Previous spectrophotometer calibration standards, such as those made from didymium glass ...
(Date:6/29/2015)... 2015  AACC, a global scientific and medical ... medicine, is pleased to announce that the impact ... has increased to 7.9 in the 2014 Thomson ... Clinical Chemistry in the top 3% of ... of the research it publishes on laboratory medicine ...
Breaking Biology Technology:Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 3AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3
... BOSTON, March 12 Vical Incorporated (Nasdaq:,VICL) announced ... of its,product development programs on Monday, March 17, ... Conference (Boston -- March 17-20)., About Vical, ... on its,patented DNA delivery technologies for the prevention ...
... 11:00 a.m. ET; 8:00 a.m. PT, VANCOUVER and ... OTC: MGIFF), a clinical-stage developer of drugs for infectious,diseases, ... March 13,2008 at 11:00 a.m. ET (8:00 a.m. PT) ... January 31, 2008 and provide an update on,company activities. ...
... (Nasdaq: IDEV ) today announced the Company will ... Care Conference, on,Tuesday, March 18, 2008 at 1:40 pm ... presentation will be web cast live and may be,accessed ... at, http://www.indevus.com ., About Indevus, Indevus Pharmaceuticals, ...
Cached Biology Technology:Vical to Present at Cowen and Company Health Care Conference 2Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference 2Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference 3
(Date:6/17/2015)... HILDEN , Deutschland und GERMANTOWN, Maryland ... Investigator ®   Produktlinie mit ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... neue STR-Testkits der Produktlinie Investigator ... DNA-Spuren in den Markt eingeführt. Die neuen Kits zur ...
(Date:6/16/2015)... /CNW Telbec/ - handyem Inc. and FlowMetric Diagnostics ... of handyem,s HPC-150 portable flow cytometer within FlowMetric ... unprecedented model of mobile laboratory platform is presented ... Pennsylvania Convention Center, ... to 18 th 2015.  By virtue of ...
(Date:6/15/2015)... -- According to a new market research ... and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image ... The Natural Language Processing Market is expected to grow ... the forecast period 2015-2020. Browse 65 ... spread   through 155 P ages and in-depth ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5
... protein that regulates gene expression may play a role in ... psychiatric disease. As reported in the latest issue of ... Bipolar Disorders, levels of SP4 (specificity protein 4) were lower ... from patients with bipolar disorder. The study suggests that normalization ...
... DST Health Solutions , LLC, today announced ... (CCHP) has implemented its PowerMHC® core claims administration platform ... new market requirements and enhance data integration. In addition, ... line service for CCHP, which supports more than 31,000 ...
... of a cellular mechanism linked to the toxicity of ... study, published in Environmental Science & Technology , ... neurological diseases such as Alzheimer,s. "I,m not implying ... Michael Plewa, lead scientist and professor of genetics in ...
Cached Biology News:Gene regulatory protein is reduced in bipolar disorder 2Gene regulatory protein is reduced in bipolar disorder 3DST Health Solutions' Integrated Care Management Suite Improves Care Quality, Population Management of 31,000+ Member Health Plan 2DST Health Solutions' Integrated Care Management Suite Improves Care Quality, Population Management of 31,000+ Member Health Plan 3Research links water disinfection byproducts to adverse health effects 2Research links water disinfection byproducts to adverse health effects 3
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
Convenient 10X buffer concentrate used to maximize binding to the solid phase in microwell ELISA. Formulated to provide optimal pH and ionic strength for binding of antibodies and some antigens. Co...
... can be used to label ... covalently bound acridinium NHS ester ... presence of hydrogen peroxide. Acridinium ... used as a detection method ...
A trigger solution for Flashlight labeled materials....
Biology Products: